CureVac Spokesman Says Co. Now Expects Initial Results From Phase 2B/3 COVID-19 Vaccine Study In Early Q2; Says Aiming To Have Critical Number Of Infections With Different Variants In Trial To Have Statistically Significant Read-Out For Certain Variants